MORRIS PLAINS, N.J., Jan. 12, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 4 studies focusing on early detection and treatment of pancreatic cancer have been accepted for presentation at the 2012 Gastrointestinal Cancers Symposium, scheduled for January 19 – 21, 2012, in San Francisco, CA. Co-sponsors of the Symposium include the American Gastroenterological Association (AGA) Institute, the American Society of Clinical Oncology, the American Society for Radiation Oncology and the Society of Surgical Oncology.
